Opdivo Set To Be First PD-1 Inhibitor In EU After CHMP’s April Drug Reviews
This article was originally published in The Pink Sheet Daily
Europe’s Committee for Medicinal Products for Human Use recommended Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for marketing approval for melanoma and also recommended Vanda’s sleep disorder therapy Hetlioz and Daiichi Sankyo’s once-daily oral anticoagulant Lixiana.
You may also be interested in...
Reviewers debated whether to approve Daiichi’s oral anticoagulant only for atrial fibrillation patients with renal impairment or a higher-than-tested dose for those with normal renal function. Disagreements over how to handle renal subgroup efficacy findings also led to differences of opinion on the need for a REMS.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.